Synthesis and evaluation of prodrugs of corticotropin-releasing factor-1 (CRF1) receptor antagonist BMS-665053 leading to improved oral bioavailability |
| |
Authors: | Richard A Hartz Vivekananda M Vrudhula Vijay T Ahuja James E Grace Nicholas J Lodge Joanne J Bronson John E Macor |
| |
Institution: | Research and Development, Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492, USA |
| |
Abstract: | A series of phosphate and ester-based prodrugs of anilinopyrazinone 1 (BMS-665053) containing either a methylene or an (acyloxy)alkoxy linker was prepared and evaluated in rat pharmacokinetic studies with the goal of improving the oral bioavailability of the parent (1). The prodrugs, in general, had improved aqueous solubility and oral bioavailability compared to 1. Prodrug 12, which contains an (acyloxy)alkoxy linker, showed the greatest improvement in the oral bioavailability relative to the parent (1), with a seven-fold increase (from 5% to 36%) in rat pharmacokinetic studies. |
| |
Keywords: | Corticotropin-releasing factor CRF Pyrazinone Prodrug |
本文献已被 ScienceDirect 等数据库收录! |
|